Medically Unnecessary Laboratory Tests: When the Order Cannot Support the Claim

Medically unnecessary laboratory tests include diagnostic tests billed to Medicare without a treating clinician’s order addressing the patient’s specific medical problem. The failure can start before a specimen reaches the laboratory: a preset panel replaces the patient’s needs, a standing order keeps generating tests, or the laboratory adds work the clinician never requested. Medicare and the taxpayers behind it pay for testing that does not serve the patient. If you work with requisitions, results or claims, you may see where the patient’s care stops explaining the testing and the billing takes over.

When Is a Laboratory Test Medically Unnecessary?

For Medicare diagnostic laboratory testing, necessity connects the test to a specific patient’s care. The Medicare ordering rule requires an order from the physician treating the patient for a specific medical problem, with the results used to manage that problem. Qualified nonphysician practitioners can also order within their authority and Medicare benefit.

The clinical decision belongs with the treating practitioner. The laboratory performs the testing and bills for it, often without holding the medical chart that explains the decision. That separation is central to how independent laboratories work. The practice knows why it wanted the test. The laboratory knows what it ran and what it charged.

A laboratory’s certificate under the Clinical Laboratory Improvement Amendments addresses its qualifications to perform testing. Patient-specific necessity still requires the order, the reason for the test and its clinical use. A paid claim leaves those questions open too: Precision Toxicology’s government agreement expressly requires reviewers to examine already-paid claims for medical necessity.

If a doctor signs a standing order but never reviews results, the question is how those results enter treatment. When a physician practice never receives definitive test results, we examine the result-delivery record alongside the treating clinician’s chart. The bill can be complete while the clinical purpose remains unexplained.

A Signed Requisition Can Hide a Preset Menu

A signature on a custom profile can authorize the same broad menu for nearly everyone in a practice. The form’s design determines whether the clinician chooses tests for the patient or simply adopts the laboratory’s preset selection.

Genotox Laboratories agreed to pay at least $5.9 million in April 2023 to resolve False Claims Act allegations involving blanket drug-testing orders and marketer payments. The claims went to Medicare and other federal health care programs. As part of the civil settlement, Genotox admitted offering custom profiles through which providers preselected tests that the laboratory then performed and billed for all or nearly all their patients. These generally fell in the highest reimbursement categories, including definitive testing for 22 or more drug classes.

The profile was customized to the provider. The admitted practice applied it to nearly every patient.

The Office of Inspector General’s laboratory compliance guidance, published in 1998, puts the decision at the individual-test level. It recommends requisition forms that ensure the ordering practitioner makes an independent medical-necessity decision for each billed test.

For standing orders during an extended course of treatment, the same guidance calls for monitoring, a fixed period of validity and renewal. It says a standing order alone is usually inadequate documentation of necessity. The signature, the tests selected, the period covered and the patient’s ongoing care all belong in the same account.

When Are Toxicology Tests Unnecessary?

Toxicology tests are unnecessary when their scope or repetition lacks a patient-specific clinical purpose. Broad profiles and automatic confirmation can replace a decision about what the treating clinician needs to learn.

Presumptive urine drug testing commonly uses immunoassays to screen for drugs or their metabolites. Definitive testing uses more specific methods, such as chromatography with mass spectrometry. The methods answer different questions and have different limits.

Urine Drug Screening: A Guide to Monitoring Tx With Controlled Substances, published in The Journal of Family Practice in 2021, explains that immunoassays can produce false-positive and false-negative results. The review describes confirmation as particularly useful when an unexpected screen conflicts with the patient’s account and would drive a significant treatment decision. It bases testing frequency on ongoing assessment, including history, prior results and changes in substance use.

The paper’s point about repetition is especially relevant to a laboratory receiving the same orders at every visit:

For an insider, it gives substance to the question behind a fixed testing schedule: what changed in the patient’s care, and did the testing change with it?

Reflex Testing Follows the Clinician’s Condition

A conditional order can request an additional test if the first result meets a criterion set by the treating practitioner. The Medicare Benefit Policy Manual gives the example of performing another test if the first is negative.

The useful comparison is between that condition and what the laboratory actually did. A laboratory protocol that adds testing to every specimen bypasses the result-dependent decision described in the order. The original request, the triggering result and the added test show whether the condition was followed.

Laboratory Medical Necessity Documentation Requirements: The Chart Behind the Bill

Laboratory medical necessity documentation requirements divide the records between the ordering practitioner and the billing laboratory. The practitioner must keep the clinical justification in the patient’s medical record. The laboratory must keep the documentation it receives and support showing that its claim accurately reflects that information.

For an unsigned clinical diagnostic order, the Medicare Benefit Policy Manual requires the physician’s intent to be clearly documented in the medical record. The chart must explain what the clinician intended.

On review, Medicare can request the order, evidence of accurate processing and the diagnostic information supplied to the laboratory. If that information fails to demonstrate necessity, the Centers for Medicare & Medicaid Services requests the relevant chart from the ordering practitioner. If the practitioner does not supply it, the rule directs CMS to deny the laboratory’s claim. The missing record can sit at the practice while the denied payment sits at the laboratory.

The Diagnosis Must Come From the Clinical Information

A laboratory cannot invent a diagnosis to obtain payment. The OIG guidance specifically addresses automated insertion of diagnosis codes without information from the ordering practitioner and reuse of earlier information outside the standing-order context.

The whistleblower complaint against Genotox alleged a concrete version of that problem:

The allegation concerns where a new claim to a federal health care program got its justification. The earlier diagnosis supplied the entry the billing system needed. Comparing the current order with the information carried forward makes that decision visible.

How Automatic Testing Reaches the Claim

Automatic testing can begin in the practice’s ordering system or in the laboratory’s menu.

The University of Miami’s May 2021 settlement resolved allegations that included unnecessary testing of kidney-transplant patients. According to the government, each patient check-in triggered a preset protocol in the electronic ordering system. Several tests allegedly reflected financial considerations rather than patient care. The trigger was arrival at the clinic.

Precision Toxicology, doing business as Precision Diagnostics, agreed to pay $27 million in October 2024 to resolve allegations of unnecessary urine drug testing and free test cups offered in exchange for specimens returned for additional testing. The government alleged that custom profiles operated as standing orders for broad testing without individualized assessment.

The cups explain why the money belongs beside the order. In the alleged arrangement, accepting a free item brought a commitment to send the specimen back for more testing.

Genetic testing carries the same patient-selection question. In its 2015 resolution, Millennium Health agreed to pay $10 million over allegations of routine genetic testing without individualized assessment. That was the genetic-testing component of a broader resolution.

The Justice Department’s September 2019 announcement of criminal charges involving cancer genetic testing described another way to manufacture orders. The charges alleged that participants paid doctors to prescribe tests without patient interaction or after only a brief phone conversation. The department also described results that often never reached beneficiaries or were worthless to their actual doctors. The order existed, but the alleged scheme had disconnected it from treatment.

Laboratory ABNs and Medical Necessity

An Advance Beneficiary Notice addresses possible patient responsibility for payment when Medicare is expected to deny a laboratory test. The treating clinician’s order and medical justification still have their own jobs.

The Medicare Claims Processing Manual’s laboratory notice provision, dated October 2003, describes advance notice that a test is expected to be noncovered as unreasonable or unnecessary and that the patient will be charged.

The OIG’s 1998 guidance also makes the laboratory responsible for producing the notice on request and says beneficiaries should not sign blank notices. For someone reviewing a file, the relevant documents are the notice for the test, the order and the medical record. A patient’s agreement to a charge supplies neither the clinician’s reason for testing nor an answer to a payment made for the referral.

Laboratory NCD and LCD Medical Necessity Rules: A Fee Is Not Coverage

Laboratory NCD and LCD medical necessity rules determine coverage nationally or within a Medicare contractor’s jurisdiction. Clinical purpose, coverage eligibility, documentation and correct coding each need support. A fee on the payment schedule does not settle the coverage question.

The applicable rule is the one for the payer, contractor, test and date of service. Molecular testing may also fall under MolDX policies in participating jurisdictions.

Genetic Eligibility Depends on the Patient and the Test

The patient’s cancer and treatment decision matter to genetic-test coverage. CMS’s Next Generation Sequencing coverage determination ties its national acquired-cancer pathway to specified advanced or recurrent cancer and a decision to pursue further treatment. Results must reach the treating physician to guide that care.

The national inherited-cancer pathway includes specific patient requirements for breast or ovarian cancer, a clinical indication and a risk factor. These are eligibility pathways for particular cancer tests, not permission to screen everyone whose insurance will pay.

Panel Unbundling Changes the Bill, Not the Work

Panel unbundling bills the component tests separately instead of billing the panel. For dates of service from January 1, 2019, the laboratory claims manual requires the panel code when all its components are performed. Medicare also requires all the defined components to have been performed before that panel code is payable.

That creates a second comparison. Medical necessity asks why the patient needed the tests. Panel coding asks whether the claim represents the work performed. The order, performance record and claim have to account for both.

What Evidence Is Needed to Prove Fraud?

Evidence connects the clinician’s decision to the testing, the claim and the people who controlled any difference. We examine how the order became laboratory work and how that work became a request for government payment.

Precision’s corporate integrity agreement shows how far that comparison reaches. It requires an order report identifying the test, patient, ordering provider, date and reason, with the requisition changed to capture that information. Its claims review reaches client registrations, orders and applicable results to assess necessity, documentation, coding and reimbursement.

We connect the order, the work, the claim and the financial arrangements with you. In healthcare billing, that means tracing who selected the tests, what reached the treating clinician and how the laboratory turned the clinical information into a charge.

Genotox’s civil settlement included claims brought by its former billing manager. That is a role with a view of the order as the billing system receives it, including the codes and information used to obtain payment. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

When the Billing Outruns the Order

If you know how a laboratory’s standing profiles, added tests or carried-forward diagnoses become claims, speak with our whistleblower experts about the decisions behind that billing. We work with you to build your strongest laboratory fraud whistleblower case around those decisions and bring in laboratory fraud whistleblower lawyers who understand testing and reimbursement. We stay beside you from that first assessment through the case.